	US 12,264,197 B2
	Anti-Vβ17/anti-CD123 bispecific antibodies
Rajkumar Ganesan, Blue Bell, PA (US); Iqbal S. Grewal, Newtown, PA (US); and Manuel Alejandro Sepulveda, West Windsor, NJ (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Appl. No. 17/437,771
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
PCT Filed Mar. 11, 2020, PCT No. PCT/IB2020/000342 § 371(c)(1), (2) Date Sep. 9, 2021, PCT Pub. No. WO2020/183245, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/816,464, filed on Mar. 11, 2019.
Prior Publication US 2022/0127359 A1, Apr. 28, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01)

CPC C07K 16/2809 (2013.01) [A61P 35/02 (2018.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)]

25 Claims

1. An isolated Vβ17 bispecific antibody or antigen-binding fragment thereof, the isolated Vβ17 bispecific antibody or antigen-binding fragment thereof comprising:

a. a first heavy chain (HC1);

b. a second heavy chain (HC2);

c. a first light chain (LC1); and

d. a second light chain (LC2),

wherein HC1 is associated with LC1 and HC2 is associated with LC2, and wherein HC1 comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and LC1 comprises a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, to form a binding site for a first antigen, and wherein HC2 and LC2 form a binding site for the second antigen.